Journal article
Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
- Iliev ME Department of Ophthalmology, University of Bern, Inselspital, Bern, Switzerland. milko.lliev@insel.ch
- Domig D
- Wolf-Schnurrbursch U
- Wolf S
- Sarra GM
- 2006-12-13
Published in:
- American journal of ophthalmology. - 2006
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Combined Modality Therapy
Female
Glaucoma, Neovascular
Humans
Injections
Intraocular Pressure
Iris
Laser Coagulation
Male
Retinal Vein Occlusion
Retrospective Studies
Vascular Endothelial Growth Factor A
Vitreous Body
English
PURPOSE
To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin).
DESIGN
Retrospective interventional case series.
METHODS
Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks.
RESULTS
IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment.
CONCLUSION
IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.
To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin).
DESIGN
Retrospective interventional case series.
METHODS
Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks.
RESULTS
IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment.
CONCLUSION
IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.ajo.2006.06.066
- PMID 17157590
- Persistent URL
- https://folia.unifr.ch/global/documents/143927
Statistics
Document views: 26
File downloads: